Jeremy Bender
CIK 1863107 · CHIEF EXECUTIVE OFFICER · last filed 2026-07-29
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$234.4K
Companies
5
Total Filings
59
Lifetime Open-Market Net
-$5.43M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BCAX | Director | — | $27.73 | — | $0 | 1 | 2026-07-29 |
| AURA | Director | 30,000 | $7.70 | $231.0K | $0 | 1 | 2026-07-08 |
| Day One Biopharmaceuticals, Inc. (DAWN) Delisted | CHIEF EXECUTIVE OFFICER | 0 | $21.53 | $0 | -$5.43M | 39 | 2026-04-23 |
| MREO | Director | 12,550 | $0.27 | $3.4K | $0 | 4 | 2026-02-27 |
| Fusion Pharmaceuticals Inc. (FUSN) Delisted | Director | — | $21.55 | — | $0 | 2 | 2024-06-04 |
Recent Filings · Page 4 of 6
59 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-05-01 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Notice (144) | −120,000 | -$2.05M | EDGAR |
| 2024-02-20 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Mixed | +12,384 | -$116.1K | EDGAR |
| 2024-02-16 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Notice (144) | −7,615 | -$116.1K | EDGAR |
| 2024-02-09 | MREO | Grant (A) | — | $0 | EDGAR |
| 2024-01-09 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-11-17 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Mixed | +5,205 | -$36.3K | EDGAR |
| 2023-11-16 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Notice (144) | −3,107 | -$36.3K | EDGAR |
| 2023-10-16 | Fusion Pharmaceuticals Inc. (FUSN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-08-17 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Mixed | +5,316 | -$41.5K | EDGAR |
| 2023-07-05 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Mixed | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.